Risky Business Part 2: SELECT’s Dirty Little Secret

Welcome to Part 2 of Novo Nordisk's masterful marketing push to turn their weight loss drugs into cardiovascular life savers. You can read Part 1 here. We'll start with an overview of the clinical trial at the centre of Novo's PR stunt, the 'Semaglutide Effects on...